Annovis Operating Income Trend from 2010 to 2022

ANVS
 Stock
  

USD 12.20  0.93  8.25%   

Annovis Bio Operating Income yearly trend continues to be relatively stable with very little volatility. Operating Income is likely to drop to -14,919,779. . Annovis Bio Operating Expenses is relatively stable at the moment as compared to the past year. Annovis Bio reported last year Operating Expenses of 14.54 Million. As of 06/27/2022, Research and Development Expense is likely to grow to about 9.1 M, while Consolidated Income is likely to drop (14.9 M).
  
Refresh
Check Annovis Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Annovis main balance sheet or income statement drivers, such as Operating Expenses of 15.7 M, Research and Development Expense of 9.1 M or Selling General and Administrative Expense of 4.8 M, as well as many exotic indicators such as Book Value per Share of 6.3, Current Ratio of 32.94 or Debt to Equity Ratio of 0.0367. Annovis financial statements analysis is a perfect complement when working with Annovis Bio Valuation or Volatility modules. It can also supplement various Annovis Bio Technical models. Please continue to the analysis of Annovis Bio Correlation against competitors.

Annovis Operating Income Breakdown

Showing smoothed Operating Income of Annovis Bio with missing and latest data points interpolated. Operating Income is the amount of profit realized from Annovis Bio operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Annovis Bio is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Operating income is a measure of financial performance before the deduction of Interest Expense; [TaxExp] and other Non-Operating items. It is calculated as [GP] minus Operating Expenses.Annovis Bio's Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Annovis Bio's overall financial position and show how it may be relating to other accounts over time.
Operating Income10 Years Trend
Decreasing
Slightly volatile
 Operating Income 
Share
      Timeline 

Annovis Operating Income Regression Statistics

Arithmetic Mean(3,394,483)
Coefficient Of Variation(155.75)
Mean Deviation 3,986,734
Median(713,937)
Standard Deviation 5,286,743
Range 14,205,842
R-Value(0.73)
R-Squared 0.54
Significance 0.004486
Slope(993,031)

Annovis Operating Income History

2019-1.6 M
2020-6.6 M
2021-14.5 M
2022-14.9 M

About Annovis Bio Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Annovis Bio income statement, its balance sheet, and the statement of cash flows. Annovis Bio investors use historical funamental indicators, such as Annovis Bio's Operating Income, to determine how well the company is positioned to perform in the future. Although Annovis Bio investors may use each financial statement separately, they are all related. The changes in Annovis Bio's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Annovis Bio's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Annovis Bio Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Annovis Bio. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Operating Income-14.5 M-14.9 M
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania. Annovis Bio operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. It employs 3 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Annovis Bio without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Crypto Correlations Now

   

Crypto Correlations

Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
All  Next Launch Module
Please continue to the analysis of Annovis Bio Correlation against competitors. Note that the Annovis Bio information on this page should be used as a complementary analysis to other Annovis Bio's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

Complementary Tools for Annovis Stock analysis

When running Annovis Bio price analysis, check to measure Annovis Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Annovis Bio is operating at the current time. Most of Annovis Bio's value examination focuses on studying past and present price action to predict the probability of Annovis Bio's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Annovis Bio's price. Additionally, you may evaluate how the addition of Annovis Bio to your portfolios can decrease your overall portfolio volatility.
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Is Annovis Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Annovis Bio. If investors know Annovis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Annovis Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
92 M
Return On Assets
-0.44
Return On Equity
-0.74
The market value of Annovis Bio is measured differently than its book value, which is the value of Annovis that is recorded on the company's balance sheet. Investors also form their own opinion of Annovis Bio's value that differs from its market value or its book value, called intrinsic value, which is Annovis Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Annovis Bio's market value can be influenced by many factors that don't directly affect Annovis Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Annovis Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine Annovis Bio value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Annovis Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.